Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

<p>Supplementary Figure 1. Expression of membranous NECTIN-4 in UC histology subtypes in PRIM (A) and MET (B). (C) depicts differential NECTIN-4 expression during metastatic spread. Intergroup comparison was calculated by non-parametric Kruskal-Wallis test.</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Niklas Klümper (15048887) (author)
Diğer Yazarlar:	Damian J. Ralser (15048890) (author), Jörg Ellinger (15048893) (author), Florian Roghmann (15048896) (author), Julia Albrecht (15048899) (author), Eduard Below (15048902) (author), Abdullah Alajati (15048905) (author), Danijel Sikic (15048908) (author), Johannes Breyer (15048911) (author), Christian Bolenz (15048914) (author), Friedemann Zengerling (15048917) (author), Philipp Erben (15048920) (author), Kristina Schwamborn (15048923) (author), Ralph M. Wirtz (15048926) (author), Thomas Horn (15048929) (author), Dora Nagy (15048932) (author), Marieta Toma (15048935) (author), Glen Kristiansen (15048938) (author), Thomas Büttner (15048941) (author), Oliver Hahn (15048944) (author), Viktor Grünwald (15048947) (author), Christopher Darr (15048950) (author), Eva Erne (15048953) (author), Steffen Rausch (15048956) (author), Jens Bedke (15048959) (author), Katrin Schlack (15048962) (author), Mahmoud Abbas (15048965) (author), Stefanie Zschäbitz (15048968) (author), Constantin Schwab (15048971) (author), Alexander Mustea (15048974) (author), Patrick Adam (15048977) (author), Andreas Manseck (15048980) (author), Bernd Wullich (15048983) (author), Manuel Ritter (15048986) (author), Arndt Hartmann (15048549) (author), Jürgen Gschwend (15048989) (author), Wilko Weichert (15048992) (author), Franziska Erlmeier (15048995) (author), Michael Hölzel (15048998) (author), Markus Eckstein (14949481) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Tumor Biology Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Antibody-drug conjugates Drug Resistance Clinical drug resistance Drug Targets Cell surface receptor drug targets Genitourinary Cancers Bladder cancer Precision Medicine Progression, Invasion & Metastasis Tumor progression Translational Research Tumor Heterogeneity
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

_version_	1849927633266016256
author	Niklas Klümper (15048887)
author2	Damian J. Ralser (15048890) Jörg Ellinger (15048893) Florian Roghmann (15048896) Julia Albrecht (15048899) Eduard Below (15048902) Abdullah Alajati (15048905) Danijel Sikic (15048908) Johannes Breyer (15048911) Christian Bolenz (15048914) Friedemann Zengerling (15048917) Philipp Erben (15048920) Kristina Schwamborn (15048923) Ralph M. Wirtz (15048926) Thomas Horn (15048929) Dora Nagy (15048932) Marieta Toma (15048935) Glen Kristiansen (15048938) Thomas Büttner (15048941) Oliver Hahn (15048944) Viktor Grünwald (15048947) Christopher Darr (15048950) Eva Erne (15048953) Steffen Rausch (15048956) Jens Bedke (15048959) Katrin Schlack (15048962) Mahmoud Abbas (15048965) Stefanie Zschäbitz (15048968) Constantin Schwab (15048971) Alexander Mustea (15048974) Patrick Adam (15048977) Andreas Manseck (15048980) Bernd Wullich (15048983) Manuel Ritter (15048986) Arndt Hartmann (15048549) Jürgen Gschwend (15048989) Wilko Weichert (15048992) Franziska Erlmeier (15048995) Michael Hölzel (15048998) Markus Eckstein (14949481)
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
author_facet	Niklas Klümper (15048887) Damian J. Ralser (15048890) Jörg Ellinger (15048893) Florian Roghmann (15048896) Julia Albrecht (15048899) Eduard Below (15048902) Abdullah Alajati (15048905) Danijel Sikic (15048908) Johannes Breyer (15048911) Christian Bolenz (15048914) Friedemann Zengerling (15048917) Philipp Erben (15048920) Kristina Schwamborn (15048923) Ralph M. Wirtz (15048926) Thomas Horn (15048929) Dora Nagy (15048932) Marieta Toma (15048935) Glen Kristiansen (15048938) Thomas Büttner (15048941) Oliver Hahn (15048944) Viktor Grünwald (15048947) Christopher Darr (15048950) Eva Erne (15048953) Steffen Rausch (15048956) Jens Bedke (15048959) Katrin Schlack (15048962) Mahmoud Abbas (15048965) Stefanie Zschäbitz (15048968) Constantin Schwab (15048971) Alexander Mustea (15048974) Patrick Adam (15048977) Andreas Manseck (15048980) Bernd Wullich (15048983) Manuel Ritter (15048986) Arndt Hartmann (15048549) Jürgen Gschwend (15048989) Wilko Weichert (15048992) Franziska Erlmeier (15048995) Michael Hölzel (15048998) Markus Eckstein (14949481)
author_role	author
dc.creator.none.fl_str_mv	Niklas Klümper (15048887) Damian J. Ralser (15048890) Jörg Ellinger (15048893) Florian Roghmann (15048896) Julia Albrecht (15048899) Eduard Below (15048902) Abdullah Alajati (15048905) Danijel Sikic (15048908) Johannes Breyer (15048911) Christian Bolenz (15048914) Friedemann Zengerling (15048917) Philipp Erben (15048920) Kristina Schwamborn (15048923) Ralph M. Wirtz (15048926) Thomas Horn (15048929) Dora Nagy (15048932) Marieta Toma (15048935) Glen Kristiansen (15048938) Thomas Büttner (15048941) Oliver Hahn (15048944) Viktor Grünwald (15048947) Christopher Darr (15048950) Eva Erne (15048953) Steffen Rausch (15048956) Jens Bedke (15048959) Katrin Schlack (15048962) Mahmoud Abbas (15048965) Stefanie Zschäbitz (15048968) Constantin Schwab (15048971) Alexander Mustea (15048974) Patrick Adam (15048977) Andreas Manseck (15048980) Bernd Wullich (15048983) Manuel Ritter (15048986) Arndt Hartmann (15048549) Jürgen Gschwend (15048989) Wilko Weichert (15048992) Franziska Erlmeier (15048995) Michael Hölzel (15048998) Markus Eckstein (14949481)
dc.date.none.fl_str_mv	2025-11-25T13:07:29Z
dc.identifier.none.fl_str_mv	10.1158/1078-0432.30707576
dc.relation.none.fl_str_mv	https://figshare.com/articles/figure/Figure_S1_from_Membranous_NECTIN-4_Expression_Frequently_Decreases_during_Metastatic_Spread_of_Urothelial_Carcinoma_and_Is_Associated_with_Enfortumab_Vedotin_Resistance/30707576
dc.rights.none.fl_str_mv	CC BY info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv	Cancer Tumor Biology Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Antibody-drug conjugates Drug Resistance Clinical drug resistance Drug Targets Cell surface receptor drug targets Genitourinary Cancers Bladder cancer Precision Medicine Progression, Invasion & Metastasis Tumor progression Translational Research Tumor Heterogeneity
dc.title.none.fl_str_mv	Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
dc.type.none.fl_str_mv	Image Figure info:eu-repo/semantics/publishedVersion image
description	<p>Supplementary Figure 1. Expression of membranous NECTIN-4 in UC histology subtypes in PRIM (A) and MET (B). (C) depicts differential NECTIN-4 expression during metastatic spread. Intergroup comparison was calculated by non-parametric Kruskal-Wallis test.</p>
eu_rights_str_mv	openAccess
id	Manara_c4cb1635120e1c79fbfd730b56a7ef0a
identifier_str_mv	10.1158/1078-0432.30707576
network_acronym_str	Manara
network_name_str	ManaraRepo
oai_identifier_str	oai:figshare.com:article/30707576
publishDate	2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv	CC BY
spelling	Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin ResistanceNiklas Klümper (15048887)Damian J. Ralser (15048890)Jörg Ellinger (15048893)Florian Roghmann (15048896)Julia Albrecht (15048899)Eduard Below (15048902)Abdullah Alajati (15048905)Danijel Sikic (15048908)Johannes Breyer (15048911)Christian Bolenz (15048914)Friedemann Zengerling (15048917)Philipp Erben (15048920)Kristina Schwamborn (15048923)Ralph M. Wirtz (15048926)Thomas Horn (15048929)Dora Nagy (15048932)Marieta Toma (15048935)Glen Kristiansen (15048938)Thomas Büttner (15048941)Oliver Hahn (15048944)Viktor Grünwald (15048947)Christopher Darr (15048950)Eva Erne (15048953)Steffen Rausch (15048956)Jens Bedke (15048959)Katrin Schlack (15048962)Mahmoud Abbas (15048965)Stefanie Zschäbitz (15048968)Constantin Schwab (15048971)Alexander Mustea (15048974)Patrick Adam (15048977)Andreas Manseck (15048980)Bernd Wullich (15048983)Manuel Ritter (15048986)Arndt Hartmann (15048549)Jürgen Gschwend (15048989)Wilko Weichert (15048992)Franziska Erlmeier (15048995)Michael Hölzel (15048998)Markus Eckstein (14949481)CancerTumor BiologyTherapeutic Research and DevelopmentClinical Research and TrialsBiological Agents & TherapiesAntibody-drug conjugatesDrug ResistanceClinical drug resistanceDrug TargetsCell surface receptor drug targetsGenitourinary CancersBladder cancerPrecision MedicineProgression, Invasion & MetastasisTumor progressionTranslational ResearchTumor Heterogeneity<p>Supplementary Figure 1. Expression of membranous NECTIN-4 in UC histology subtypes in PRIM (A) and MET (B). (C) depicts differential NECTIN-4 expression during metastatic spread. Intergroup comparison was calculated by non-parametric Kruskal-Wallis test.</p>2025-11-25T13:07:29ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30707576https://figshare.com/articles/figure/Figure_S1_from_Membranous_NECTIN-4_Expression_Frequently_Decreases_during_Metastatic_Spread_of_Urothelial_Carcinoma_and_Is_Associated_with_Enfortumab_Vedotin_Resistance/30707576CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307075762025-11-25T13:07:29Z
spellingShingle	Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance Niklas Klümper (15048887) Cancer Tumor Biology Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Antibody-drug conjugates Drug Resistance Clinical drug resistance Drug Targets Cell surface receptor drug targets Genitourinary Cancers Bladder cancer Precision Medicine Progression, Invasion & Metastasis Tumor progression Translational Research Tumor Heterogeneity
status_str	publishedVersion
title	Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
title_full	Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
title_fullStr	Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
title_full_unstemmed	Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
title_short	Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
title_sort	Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
topic	Cancer Tumor Biology Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Antibody-drug conjugates Drug Resistance Clinical drug resistance Drug Targets Cell surface receptor drug targets Genitourinary Cancers Bladder cancer Precision Medicine Progression, Invasion & Metastasis Tumor progression Translational Research Tumor Heterogeneity

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance

Benzer Materyaller